Connective Tissue Gene Tests, or CTGT, this week announced the availability of 33 new tests using its next-generation sequencing and microarray technologies.
Twenty of the new panels can be run on its High-Density Targeted Array platform, an Agilent Technologies-manufactured chip for copy number variation detection.
These include tests for genes associated with different types of spondylocostal dysotosis, Norrie disease, pseudoxanthoma elasticum, serpentine fibula-polycystic kidney syndrome, Alagille syndrome, arterial calcification, cleidocranial dysplasia, Ehlers-Danlos syndrome, exudative vitreoretinopathy, Hajdu-Cheney syndrome, hereditary hemorrhagic telangiectasia, and metaphyseal dysplasia.
The Allentown, Pa.-based company charges $1,190 per first gene tested with the array and $590 per additional genes tested.